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Summary 
 
The HTA-funded smoking, nicotine and pregnancy (SNAP) trial will investigate 
whether or not nicotine replacement therapy (NRT) is effective, cost-effective and 
safe when used for smoking cessation by pregnant women.  Over two years, in 5 
trial centres, we will randomise 1050 pregnant women who are between 12 and 
24 weeks pregnant as they attend hospital for ante-natal ultrasound scans.  
Women will receive either nicotine or placebo transdermal patches with 
behavioural support.  The primary outcome measure is biochemically-validated, 
self-reported, prolonged and total abstinence from smoking between a quit date 
(defined before randomisation and set within two weeks of this) and delivery. At 
six months after childbirth self-reported maternal smoking status will be 
ascertained and two years after childbirth, self-reported maternal smoking status 
and the behaviour, cognitive development and respiratory symptoms of children 
born in the trial will be compared in both groups.  
SNAP trial protocol Final version 7.0 11 June 2009 
 
  
SNAP trial protocol Final version 7.0 11 June 2009 
 
  
Contents
 
  Page 
Number 
 
1. Background 3 
 
2. Hypothesis 
 
4 
3. Interventions 4 
 
4. Randomisation procedure 5 
 
5. Outcome measures 5 
 
6. Number of Patients Required 7 
 
7. Eligibility criteria 7 
 
8. Trial process 8 
 
9. Data collection 12 
 
10. Interventions 15 
 
11. Statistical analysis plan 15 
 
12.  Safety reporting 
 
17 
13. Publication policy 18 
 
14. Trial steering committee 18 
 
15. Data monitoring and ethics committee 19 
 
16. Centres 19 
 
17. Funding 20 
 
18. References 21 
 
19. Data collection forms 22 
 
 Appendix A: Trial process 
 
23 
 Appendix B: Trial materials 25 
 
SNAP trial protocol Final version 7.0 11 June 2009 
 
 - 2 -  
SNAP trial protocol Final version 7.0 11 June 2009 
 
 - 3 -  
1. Background 
 
Maternal smoking during pregnancy harms unborn children and, as up to 30% of 
pregnant women smoke1, it is a significant public health problem.  The adverse 
effects of smoking during pregnancy include an increased risk of miscarriage and 
stillbirth, accounting for 4000 deaths annually, and of pre-term birth and low 
birth weight leading to increased perinatal morbidity2;3. Children of mothers who 
smoke whilst pregnant are at increased risk of neo-natal mortality, sudden infant 
death syndrome and asthma2.  Maternal smoking whilst pregnant is also 
associated with an increased risk of attention deficit and learning problems in 
childhood.3;4  Currently only around 25% of pregnant smokers stop for even part 
of their pregnancy and, of these, around two thirds re-start post-natally1.     
 
Effective methods for promoting smoking cessation by pregnant women are 
required.  The most effective smoking cessation therapy in non-pregnant smokers 
is a combination of behavioural support and pharmacotherapy with either nicotine 
replacement therapy (NRT)5 or bupropion.6  Behavioural support alone can 
increase smoking cessation rates by up to 7%7  and the addition of 
pharmacotherapy increases this further by 1.5 to 2-fold.  Behavioural support is 
usually provided without pharmacotherapy, however, because of concerns that 
drug therapy may harm the fetus.8  This is understandable for bupropion, but is 
far less logical for nicotine. 
 
Pregnant women who smoke will already expose their unborn children to nicotine.  
Nicotine has well documented potential adverse effects in pregnancy, since it is a 
vasoconstrictor and nicotine from cigarettes causes dose-related increases in 
maternal blood pressure and heart rate and has lesser effects on the fetal heart 
rate.9  In rats chronic nicotine exposure is associated with dose-dependant 
alterations in behavioural and cognitive responses, CNS toxicity and a diminished 
adrenal response to hypoxia that, in humans, could pre-dispose to sudden infant 
death syndrome.9  Consequently, nicotine may also be responsible for the 
attention deficit and learning problems that are described above.4  Cigarette 
smoke, however, contains numerous other toxins in addition to nicotine and it is 
not known which of these actually cause harm, though the fetal effects of nicotine 
have been most widely studied. The cardiovascular effects of nicotine from NRT 
are less than those observed from smoking and regular NRT use generates lower 
plasma nicotine concentrations (when body weight is accounted for) than those in 
the animal experiments described above.9  There is also no evidence that NRT 
use in pregnancy results in higher plasma nicotine concentrations than smoking9.  
For these reasons, and because using NRT in pregnancy results in exposure to 
only nicotine and no other toxins, there is expert consensus that NRT use is safer 
than smoking in pregnancy as long as pregnant women using NRT do not receive 
more nicotine from NRT than they would have done by smoking10; 11.  It is 
difficult, though, for health professionals to give clear guidance to pregnant 
women on using NRT when the safety of NRT in pregnancy is justified primarily 
on theoretical grounds and its efficacy has not been established. 
 
To date, evidence on the effectiveness of NRT in pregnancy comes from 3 studies 
and is inconclusive.12-14  Two of these studies were trials investigating   NRT as 
transdermal patches12;13 but one13 was stopped after only 40 patients had been 
randomised.  The other12, however, randomised 250 women but produced no 
clear evidence that NRT was effective, since the odds ratio for smoking cessation 
using NRT versus placebo was 1.1 with a 95% CI of 0.7 to 1.8.  This odds ratio is 
much lower than that obtained from meta-analysis of trials of NRT patches in 
non-pregnant subjects (OR, 1.74) 5 and raises questions about whether using 
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NRT in pregnancy is effective for smoking cessation.  The third study was not 
placebo controlled and randomised women to intensive behavioural support with 
an additional option to use NRT patches and / or gum14 or a ‘normal care’ group 
which received only very minimal smoking cessation advice. Although, 75 women 
in this trial opted to use NRT, this design makes it difficult to disentangle any 
effect of NRT from that of intensive behavioural support. Where reported, no 
harmful effects of NRT were demonstrated in these 3 studies.  In the larger patch 
trial12, babies born in the NRT group were significantly heavier than others [mean 
birth weight (adjusted for prematurity) difference = 186g (95%CI 35,336g)], 
suggesting that pure nicotine as NRT has less impact on fetal growth in utero 
than smoking. Additionally, in the trial which allowed a group of women to use 
either NRT patches or gum or a combination of these, mean birth weights in 
fetuses born after 37 weeks were not statistically different between the 2 trial 
groups [non-significantly lighter (by 32g) in NRT group].  In both trials that 
reported the distribution of low birth weight infants between groups12;14, no 
significant differences were noted. 
 
It has recently become apparent that conventional doses of nicotine contained in 
NRT may be insufficient for pregnant women and this may explain the negative 
findings from the one trial of NRT in pregnancy.  In pregnancy, the metabolic 
clearances of nicotine and cotinine (the principal metabolite of nicotine) are 
increased by 60% and 140% respectively15. Accordingly, even when pregnant 
women take standard doses of NRT for adequate periods, these may still be 
ineffective because they may require higher doses of NRT to replace the nicotine 
they would have received via smoking.  Higher doses of NRT might, therefore, be 
needed in pregnancy, but because there is very little human-subject research into 
the effects of nicotine on the developing fetus, it is not known whether these 
might increase the risk of fetal damage.  Until the effectiveness of the current 
conventional dose of NRT is established, it is hard to justify trials of higher ones.  
 
In summary, although consensus opinion suggests that taking NRT during 
pregnancy is likely to be safer than smoking10; 8;11;16, there is little direct trial 
evidence to support this and we do not know if NRT is actually effective in 
promoting smoking cessation amongst pregnant smokers.  The SNAP trial will 
produce direct evidence on these important questions. 
 
2. Hypothesis 
 
The SNAP trial will investigate whether or not NRT is more effective than placebo 
in achieving smoking cessation for women who and are between 12 and 24 weeks 
pregnant, who currently smoke 5 or more cigarettes daily and who smoked 10 or 
more cigarettes daily before pregnancy.   
 
3. Interventions 
 
Treatment group: Pregnant women will receive an eight week course of 15mg / 
16hr NRT transdermal patches.  Although many studies have used longer 
courses, there is no evidence that these are more effective.5  Patches will be 
issued in conjunction with individual behavioural support (Section 10) which is an 
effective smoking cessation intervention in pregnancy.7  Four weeks after their 
quit dates, women who are not smoking will be issued with a second four week 
supply of patches if required.  
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Control group:  Women in the control arm of the trial will receive an identical 
placebo NRT patch and the same behavioural support as those in the treatment 
group.  In both control and intervention groups, participants will be blind to their 
group allocation. 
 
4. Randomisation procedure 
 
After collecting pre-randomisation baseline data (section 9), exhaled carbon 
monoxide readings will be taken from women and assuming that readings 
indicate that women do smoke [cut off 8 ppm17], informed consent for trial entry 
will be sought.  After consenting to trial entry, women will receive an initial 
behavioural support session (section 10) before being randomised.    
 
Randomisation will be via the Nottingham Trials Unit web-based database and 
randomisation service.  In each centre the recruiting research midwife (RM) will 
have a username and password.  (S)he will log on to the trial website that hosts 
the trial database (https://ctsu.nottingham.ac.uk/snap/login.asp), confirm that 
the patient eligibility criteria are all met and enter an agreed minimum amount of 
registration data about the participant and centre before randomisation is 
possible. Data to be entered at this stage are found in section 9.  The computer 
will then issue a trial number which will be the unique identifier for the trial 
participant and a trial pack number which will reflect the treatment allocated. 
Randomisation will be stratified by trial centre only.  
 
Numbered packs of active and placebo patches will be distributed by Queen’s 
Medical Centre pharmacy and stored in either the local pharmacy or the 
participating ante-natal/ultrasound clinics, depending on local agreements or 
arrangements. After randomisation, a prescription with a container number will 
be generated by the database. The local pharmacy or research midwife will select 
the patch pack with the appropriate container number and issue this to the 
participant. The research midwife and the trial participant will both be blind to 
group allocation. When research midwives visit women at home to enrol them 
into the trial, immediate internet randomisation will not be possible.  In this 
circumstance the research midwife will return to her / his hospital base to 
randomise the enrolled woman and the appropriate trial pack will be posted to 
the trial participant.  
 
5. Outcome measures 
 
Primary end point:  Self-reported, prolonged and total abstinence19 from 
smoking or the use of any non-pharmacological 
nicotine containing substances between a quit date 
set within two weeks of randomisation and 
immediately prior to childbirth and validation of 
abstinence from smoking at this point by both 
exhaled CO measurementa  and salivary cotinine 
estimationa. 
 
Permitted timing and rules of data collection:  
 
Self reported smoking data will be used if this is collected within i) eight weeks of 
the one month follow up point and ii) within one month of delivery.  
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Biochemical validation data will be used if this is collected within one month of 
any data collection point. Biochemical validation of self reported, prolonged 
smoking cessation will use exhaled CO measurement (at one month) and, 
additionally, salivary cotinine estimationa at delivery.   
 
Prolonged abstinence from smoking will be considered to have occurred when no 
smoking is reported between the quit date and delivery (or other follow up point). 
For the purposes of attributing positive or negative primary outcomes, very 
occasional, minor lapses during reported abstinence will not be counted as a 
return to smoking unless women report smoking more than 5 cigarettes in total 
between their quit date and delivery. 
 
 
  
Secondary end points: 
 
a) Smoking 
 
1. Self reported, prolonged abstinence from smoking between quit date and 
one month.  
2. Self reported, prolonged abstinence from smoking between quit date and 
delivery. 
3. Self reported, prolonged abstinence from smoking between quit date and 
delivery, with biochemical validation of this at both one month follow up 
and delivery. 
4. Self reported smoking cessation for previous 24hr period at delivery 
validated by exhaled CO and saliva cotinine estimation. 
5. Self reported, prolonged abstinence from smoking between quit date and 
6 months after delivery. 
6. Self reported smoking cessation for previous 7 day period at 6 months 
after delivery.  
7. Self reported, prolonged abstinence from smoking between quit date and 
2 years after delivery. 
8. Self reported smoking cessation for previous 7 day period at 2 years after 
delivery.  
 
 
b) Fetal loss and morbidity 
 
1. Miscarriage (less than 24 weeks gestation) and stillbirth (24 weeks 
gestation and over) 
2. Neonatal death (i.e. from birth to 28 days) 
3. Post-neonatal death (29 days to 2 years) 
4. Individualized birth weight Z score (i.e. birth weight adjust for gestational 
age, maternal height, maternal weight at booking and ethnic group). 
5. Apgar score 
6. Cord blood ph 
7. Gestational age at birth 
8. Intraventricular haemorrhage 
9. Neonatal enterocolitis 
10. Neonatal convulsions 
11. Congenital abnormality  
 
c)  Maternal morbidity and mortality 
 
                                                 
a
 cut offs are 8 ppm for exhaled CO and 10ng/ml for salivary cotinine17 
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1. Maternal mortality 
2. Mode of delivery  
3. Proteinuria 
4. Hypertension in pregnancy 
 
d) Early childhood outcomes 
 
1. Behaviour and development at 2 years  
2. Disability at 2 years  
3. Respiratory symptoms at 2 years  
 
e)  Health economic data  
 
1. Duration of maternal hospital admission for childbirth 
2. Duration of any admission (of baby) to special care 
3. Health status at 6 months (EQ5D)20 
 
 
6. Number of patients required 
 
Sample size:  We need to recruit 525 women into each arm of the study. A trial 
with 500 women in each arm would detect an absolute difference of 9% in 
smoking cessation rates between the two groups immediately before childbirth 
with a two-sided significance level of 5% and a power of 93%.  We anticipate that 
up to 5% of women will be lost to follow up and inflate our sample size (of 500) 
by a factor of 1.05 to allow for this.  This size of study would allow us to detect 
smaller treatment effects with lower power.  For example, we would have 80% 
power to detect an absolute difference in cessation rates of 7%.   
 
Justification:   A Cochrane review has shown that approximately 10% of women 
who are still smoking at the time of their first antenatal visit will stop smoking 
with usual care and a further 6% to 7% will stop as a result of a formal smoking 
cessation program using intensive behavioural counselling15.  This means that in 
our control group (placebo plus intensive behavioural counselling) we can expect 
a smoking cessation rate of around 16%. The most recent Cochrane review of 
NRT, reports a treatment effect (odds ratio) for transdermal patches of 1.74 
95%CI (1.57-1.93)5.  Consequently, if we were to find NRT as effective in 
pregnancy as it is generally, we could expect a smoking cessation rate of 
approximately 25% in our treatment group (NRT plus intensive behavioural 
counselling).   
 
 
7. Eligibility criteria 
 
Inclusion criteria:  Eligible women are aged 16 to 50, between 12 and 24 
weeks pregnant, who report smoking at least ten cigarettes daily before 
pregnancy and who still currently smoke at least five cigarettes daily.  They also 
must have an exhaled CO reading at least 8 ppm. Women may only enrol into the 
trial once and may participate in other non-conflicting research projects. 
 
Exclusion criteria:  Women with the following contraindications to the use of 
NRT will be excluded: severe cardiovascular disease, unstable angina, cardiac 
arrhythmias, recent cerebrovascular accident or TIA, chronic generalized skin 
disorders or known sensitivity to nicotine patches, chemical dependence / alcohol 
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addiction problems.  Also, women who cannot give informed consent and those 
with known major fetal anomalies will be excluded.  IUGR is not an exclusion 
criterion. 
 
8. Trial process 
 
Diagrams in Appendix A summarise the trial process. 
All trial materials (e.g. PIS and questionnaires) appear in Appendix B. 
 
Recruitment:  All pregnant women between 12 and 24 weeks into pregnancy 
who smoke and are interested in stopping smoking are potentially recruits to the 
study.  Three methods of recruitment will be used:  
a) It is usual practice in most areas for the community midwives to routinely 
ask women at their booking appointment about smoking status and 
whether they would like help to stop smoking. This information is then 
passed to the local smoking cessation service. These referred women will 
be sent a patient information sheet by the smoking cessation service and a 
letter asking whether they would be interested in participating in the trial. 
Women who were eligible and interested would be seen by the research 
midwife for consent and data collection as below. If they were not 
interested or eligible they would be seen by the smoking cessation service 
as per normal practice. 
b) Brief information about the trial and patient information sheets (PIS) will 
be posted to all women who attend trial site hospitals for ante natal care 
with their routine antenatal ultrasound scan appointment letters (scans 
are usually performed at between 12 and 20 weeks gestation). In each 
trial hospital, a research midwife (RM) working with a clerical assistant will 
use a systematic method to identify smokers who are interested in 
participating from all women attending for ultrasound examinations.  
During piloting a questionnaire was used for this (example in Appendix B) 
and a similar instrument could be used in any or all of the trial centres. 
The final method of identifying eligible patients will be agreed with the 
Chief Investigator.  Research midwives will also agree a method for 
monitoring the numbers of women identified as potentially eligible to join 
the trial and the proportion of these that eventually enrol. 
c) As an alternative to b) above, a leaflet advertising the trial and/or a 
questionnaire which identifies women who are interested in participating in 
the trial will be posted to all women who attend trial site hospitals for 
antenatal care with their routine antenatal ultrasound scan appointment 
letters or given to women by their community midwife at an antenatal 
appointment.  Women who are interested in joining the trial will be invited 
to contact the research midwife directly or when they attend hospital for 
their ultrasound scans.  These women will be sent / given a PIS to 
consider and will be contacted again after 24 hours to ascertain whether or 
not they want join the trial.  After this, consent and other trial procedures 
will be followed as described below.  
 
Consent:  Women who are interested in participation will be asked to discuss this 
with the research midwife.  The research midwife will ascertain if women are 
eligible to join the study and have read the PIS at least 24 hours earlier.  If they 
have read the PIS, the research midwife will answer any questions that women 
have about trial enrolment and seek informed consent to: 
    
i)  trial participation 
ii)  collection of follow up data on materno-fetal outcomes from medical  
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records   
iii) participants' registration with the Office for National Statistics  
iv)  collection of a blood sample for cotinine estimation and DNA extraction &  
storage  
v) collection of saliva samples for cotinine estimation  
vi) potential future contact for follow up studies by University of Nottingham 
based investigators 
 
If women have not read the PIS, but express an interest in the study, they will be 
given a copy.  These women will be contacted after 24 hrs and if they are still 
interested in enrolling in the study, informed consent will be sought.  
 
Once consent is recorded, baseline data, saliva, blood samples and exhaled CO 
readings are obtained.  Next the research midwife delivers the first session of 
behavioural support to the participant during which a quit date which is within 2 
weeks when they will start using transdermal patches is agreed.  
 
Registration & randomisation:  Immediately after the behavioural support 
session, the research midwife uses a PIN to log on to the University of 
Nottingham internet randomisation service and enters the mandatory 
enrolment data (section 9), without which randomisation will not be permitted.  
The participant is automatically allocated a trial number (i.e. unique ID) and a 
trial treatment pack number which identifies the treatment required and the RM 
issues the corresponding trial treatment pack.   
 
Many trial participants will need a home visit for consenting, intensive behavioral 
counseling and subsequent randomization.  In this situation, the research midwife 
(RM) will ensure that all base line data including the mandatory enrolment 
data is collected whilst visiting the participant.  The RM will return to base and 
randomise the participant via the internet before posting an appropriate 
treatment pack to the study participant. 
 
The research midwife then sends letters to the participant’s general practitioner 
and hospital obstetrician to inform them that she is enrolled in the trial.  One 
copy of the consent form is placed in the hospital medical records, another 
accompanies the letter to the GP and the third is sent to the Trial Office. 
 
Further behavioural support:  The research midwife will contact the participant 
on their quit day and three days afterwards. The research midwife will give the 
participant contact details for the local NHS stop smoking service and also pass 
the participants’ details to this service.  Participants will receive further 
behavioural support sessions from the NHS stop smoking service according to an 
agreed format, or from the research midwife if other local support is not available 
or not wanted by the participant. 
 
Data handling:  RMs will enter the data which they collect on to a secure 
database hosted by the University of Nottingham via an internet connection and 
will also make paper copies of data collection to allow audit.  Once data collection 
at any one time point (e.g. baseline or one month) is complete, the research 
midwife will post a copy of the data collection sheet to the Trial Office. Infant 
records within the database will be created from within maternal ones and will 
automatically be linked to maternal and sibling trial records. 
 
Biological samples 
i) For DNA extraction, 2x5ml EDTA blood samples are required. These can be 
refrigerated or frozen (if later than 24 hrs elapses between collection and 
dispatch).  If frozen, this needs to be to -20◦ centigrade. Samples will be 
SNAP trial protocol Final version 7.0 11 June 2009 
 
 - 10 -  
dispatched to Professor Ian Hall at the University of Nottingham for long term 
archiving.  Frozen samples require non-glass tubes.  
 
ii) Blood for serum cotinine estimation (5ml sample minimum) need to be placed 
in BD Gold top tubes (or equivalent).  These need to be frozen as per i) above 
before transport to the Nottingham Trial Coordination Team prior to dispatch to 
Professor Michael Coughtrie at the University of Dundee. 
 
iii) Saliva for salivary cotinine estimation is also transported to Dundee after 
collection.  
 
All frozen samples need to be transported on ice in non-glass containers labelled 
with: 
 
• Trial number  
• Hospital number 
• Subject’s initials 
 
Withdrawal from patch treatment: If for any reason, a participant terminates 
patch treatment, every effort must still be made to collect follow up data. 
 
Follow-up at one month after agreed quit date:  If required, participants will 
be seen by the research midwife (RM) for further supplies of patches.  To allow 
some flexibility this follow up will occur between 3 and 6 weeks after 
randomisation.  The RM will contact participants to ascertain women’s smoking 
status and those who report not smoking regularly (confirmed by exhaled CO 
measurement) and who wish to receive a further supply of patches will be issued 
with a new trial treatment pack number (obtained by the RM from the online 
database) and will receive a corresponding treatment pack (containing 4 weeks’ 
patches).  A saliva sample to measure cotinine levels on treatment will be taken if 
women are not smoking and are still wearing the patches at one month. The Trial 
Office will send one postal questionnaire asking about smoking status to women 
whom the research midwife has been unable to contact at one month.  When 
women report continued smoking cessation but do not wish to receive further 
NRT, the research midwife will arrange CO validation of this, visiting them at 
home, if necessary. 
 
Follow-up immediately before childbirth:  When participants are admitted to 
hospital whilst in established labour prior to childbirth, Delivery Suite staff will be 
asked to contact the research midwife who will visit participants to ascertain their 
self-reported smoking status and use of transdermal patches.  Women who report 
abstinence from smoking in the previous 24 hours will be asked by the research 
midwife to perform exhaled CO testing and provide a saliva sample for cotinine 
estimation.  The RM will have overall responsibility for data collection and will 
arrange with Delivery Suite staff for this to be obtained in her / his absence.    
The RM will telephone those missed whilst in hospital as soon as possible 
afterwards (within 4 weeks maximum) to collect smoking behaviour data.  Where 
participants report smoking cessation, the research midwife will measure their 
exhaled CO readings and obtain a saliva sample for cotinine estimation, visiting 
women at home if necessary.   
 
Further infant, fetal and maternal data will be obtained from medical records 
(section 9c) 
 
Data monitoring by RM between data collection points: These data are 
required to ensure that the Data Monitoring and Ethics Committee is provided 
with adequate information to form an opinion concerning trial safety: 
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Development of major fetal abnormality between randomisation and labour onset 
Miscarriage and stillbirth between randomisation and labour onset 
Maternal death between randomisation and labour onset 
Hospital admission 
 
Each month the Trial Office will provide RMs in the centres with a list of trial 
numbers for participants who are still pregnant.  The RM will use these to access 
subjects’ computer records to obtain the information listed above. In the event of 
a hospital admission the RM will assess whether or not a serious adverse event 
has occurred and act accordingly (Section 12).  If the RM enters a miscarriage or 
stillbirth into the database, this will automatically prevent further infant follow up 
and the RM will liaise with the mothers’ obstetrician to determine whether or not 
asking for follow up information concerning smoking behaviour around the 
anticipated time of delivery is acceptable. Major fetal abnormalities will also be 
reported to the trial office who will review these individually before deciding 
whether or not the participant should be allowed to continue within the trial. 
 
Registration with Office for National Statistics:  The Trial Office will “flag” 
participants (women and babies) with the Office for National Statistics (ONS) 
[now called the NHS Information Centre] at birth to facilitate follow up. Each 
week during the 2 year follow up period, the ONS will inform the trial team of any 
post-neonatal (i.e. between 29 days and 2 years) or maternal deaths. 
 
Procedure for administering postal follow up questionnaires:  Appendix A 
summarises the procedure for follow postal up after delivery.  After infant deaths, 
questionnaires will not be sent and, where maternal deaths are reported, infants’ 
general practitioners will be consulted about the appropriateness of continued 
follow up.  The Trial Office will send questionnaires directly to study participants 
using contact details provided at study recruitment.  For non-respondents or 
where questionnaires are returned labelled “not at this address”, the office will 
check participants’ addresses by contacting infants’ grandparents and, if 
necessary, the ONS / NHS Information Centre (NHSIC).  ONS / NHSIC will trace 
the infant or mother and provide details of the Primary Care Trust (PCT) which 
provides their NHS health services and the Trial Office will then contact the 
infant’s general practitioner so that a questionnaire can be sent. To maintain 
contact between researchers and participants, study infants will be sent 
Christmas cards and birthday cards.   
 
Immediately following childbirth: When appropriate, mothers will be sent or 
given a simple “Congratulations on the birth of their baby” card. 
 
Follow-up 6 months after childbirth:  A postal questionnaire, with one postal 
and one telephone reminder, will be used to collect the data items specified in 
Section 9d, below.  
 
Follow-up 1 year after childbirth:  Before infants’ 1st birthdays, parents will 
be sent a 1st birthday card  and a questionnaire to collect the data items specified 
in Section 9e, below.  Non-respondents will be sent a questionnaire reminder and 
then followed up by telephone. 
 
Follow-up 2 years after childbirth  
 
i) Parent questionnaire:  Four weeks before infants’ 2nd birthdays, we will 
dispatch to parents a questionnaire and two weeks later, all participating infants 
will be sent a 2nd birthday card, with questionnaire non-respondents being sent a 
reminder . Parents who do not respond after two questionnaires will be followed 
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up by telephone. The questionnaire will measure child behaviour, development, 
hospital admissions, respiratory symptoms and maternal smoking behaviour and 
will use standard questions to record parents’ reports of infants’ respiratory 
symptoms21 and behaviour22, the appropriate ‘Ages and Stages’ questionnaire35, 
with reference to the evidence base for questionnaire design24.  It will also include 
simple questions designed to measure children’s disability according to a standard 
definition.25 Three methods that have been demonstrated to improve postal 
returns of questionnaires will be used.36 Before the questionnaire is sent a card 
will be sent to the parent reminding them that they will be receiving a 
questionnaire shortly, and asking them to inform us of any change of address. 
When the questionnaire is sent, a £5 voucher will be enclosed along with a 
colouring competition for the child. The colouring competition will have a £50 
voucher prize, with a winner chosen 3 times per year.    
 
ii) Health professional questionnaire: When parents do not respond to the 2 
year follow up questionnaire described above, we will attempt to obtain responses 
to items measuring children’s disability from health professionals. To do this, we 
will post to participants’ general practitioners (GPs) a very short questionnaire 
containing only items to measure children’s disability which correspond to those 
that were on the questionnaire sent to parents.  These items are designed to be 
easily completed using medical or health visitors’ records.  Health professionals 
completing these questionnaires require relatively little knowledge of the patient 
and GPs will be asked to complete them.  If GPs cannot complete questionnaire, 
they will be asked to forward these to children’s’ health visitors (HV).  We will use 
an initial postal and subsequent telephone reminder to GPs to obtain the required 
information.  Items used will be based on those included in a previously-used 
questionnaire which has been validated and used with GPs and HVs 26;27’.     
 
Expected start date:     1st   April       2006  
Expected completion date:    31th March           2013 
 
9. Data collection 
 
This section specifies the items of data collect at different points during the trial. 
a) Baseline (i.e. pre-randomisation) data collection 
Although online forms will allow data to be inputted to an online database, a 
paper copy of data will be kept for audit purposes.  
i) Mandatory enrolment data (i.e. required for randomisation): The 
RM will collect the following data from participants immediately after obtaining 
informed consent.  The RM must enter the following data items about 
participants to the online database before randomisation is permitted: 
 
DoB (valid range equiv to age 16-50) 
participant’s initials 
hospital number 
daily number of cigarettes smoked before pregnancy28 
daily number of cigarettes smoked currently28 
agreed gestational age at time of randomisation (valid range 120-246) [estimated 
delivery date will be calculated automatically within database] 
time elapsed since last cigarette 
exhaled CO reading of at last 8ppm 
blood sample requested (for cotinine assay, DNA extraction & storage) 
indication that patient has signed consent form 
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indication that participant’s contact details have been recorded on paper (see 
below) 
agreed quit date 
 
ii)  Remaining baseline data for online entry:  The following data will be 
collected with above data and the RM will also enter this on to the online 
database but entering these variables will not be mandatory before online 
randomisation is permitted.  
 
NHS number (for ONS registration) 
ethnic group 
age left full time education 
number of previous births beyond 24 weeks (valid range 0-12) 
time to first cigarette of day29 
partner’s smoking status 
maternal height 
maternal weight at booking appointment 
saliva sample 
 
 
iii) Baseline data stored on paper and secure database:   
Participant name and contact details (including landline / mobile telephone 
number & postcode) 
previous surname(s) – for ONS registration 
Participant’s general practitioner and / or name of practice plus practice address 
grandparents’ contact details, including phone numbers 
 
 
b)  One month after quit date:  RM collects data from those who return.  
Postal questionnaires sent from NTCT to those who do not. The following data are 
collected: 
 
RM notes whether or not follow up occurs and the date of any follow up.  RM also 
inspects participants’ supply of patches to calculate the number used. 
 
Smoked at all in the previous 24 hrs 
Smoked since quit date (further details on outcomes form 1) 
Exhaled CO reading 
On how many days have patches been used? 
On how many days (if any) have non-trial patches been used? 
How many behavioural support sessions with NHS stop smoking services used 
(telephone & face to face)? 
Saliva sample for cotinine estimation taken if not smoking and patches still used 
 
 
c)  Upon admission for childbirth or as soon as possible afterwards:  
The following data are recorded by the RM or delivery suite staff: 
 
Date of follow up / exhaled CO reading or saliva sample 
Smoked at all in the 24 hrs prior to delivery 
Smoked between quit date and delivery 
Both of,  i) exhaled CO reading & ascertainment date ii) saliva   
  sample (for cotinine) if not smoking at delivery 
On how many days have patches been used? 
On how many days (if any) have non-trial patches been used? 
How many behavioural support sessions with NHS stop smoking services used 
(telephone & face to face)? 
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i) These data obtained by RM from maternal or infant medical records:  
 
maternal  
hypertension (>140/90) on 2 occasions (excluding labour) 
miscarriage ( between randomisation and 24 weeks) 
labour onset (spontaneous, induced, no labour) 
mode of delivery (SVD, instrumental, caesarean) 
ante natal or post natal maternal hospital admission 
infant 
baby initials 
D.O.B 
Gender 
Baby NHS number 
Prompt for RM to confirm full name and address and contact details of baby and 
to record these on paper (see below) 
Prompt for RM to make a new record of contact details if these have differed from 
previous (i.e. maternal) ones 
baby hospital number 
birth weight 
Number of births 
if multiple birth, indicate number and birth order 
live or stillbirth? 
cord ph < 7.0 
Apgar <7 at 5min 
Gestational age at birth -   to be calculated within database from gestation at 
      recruitment  
 
These infant personal details will be recorded on paper and secure database: 
 
baby name 
baby address (inc postcode) 
 
 
ii) These data obtained by research midwife from infant medical records 
 after discharge: 
  
If live birth ? live on leaving hospital 
ventilation > 24 hrs 
necrotising enterocolitis 
neonatal convulsions 
admitted to special care 
intraventricular haemorrhage (4 categories) 
congenital abnormality present (y/n).  If y then free text to describe this. 
 
 
See Appendix A for diagram explaining follow up procedure after birth. 
 
d)  Six months after delivery:  The following data will be requested:  
 
Smoking status 
Length of maternal inpatient stay for delivery of > 24 hours duration (if any) 
Any infant neonatal admission to special care 
Length of any infant inpatient stay on special care 
Maternal use of NRT / NHS stop smoking services since childbirth, 
Infant feeding method  
EQ5D questionnaire20 
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e)  At 1 year after delivery:  The following data will be requested:  
smoking status, respiratory symptoms, infant hospital admissions for respiratory 
illness and other causes, and infant feeding method  
 
e)  At 2 years after delivery:  The following data will be requested: 
 
Parent questionnaire - Smoking status, infant behaviour, development, 
respiratory symptoms and hospital admissions.  
Health professional questionnaire - Child’s disability   
 
10.   Interventions 
 
Details of NRT patches are given in section 3.  Details of behavioural support 
follow.  The first behavioural support session will be provided at recruitment by a 
research midwife who has been trained in smoking cessation methods in 
accordance with national standards30 and who has dedicated time for this task.   
Models of behavioural support that are effective in pregnancy vary greatly7 and in 
non-pregnant subjects, behavioural support following very different psychological 
models are all equally effective31.  We will, therefore, standardise the first support 
session to include information on: 
 
i)   the harmful effects of smoking in pregnancy 
ii)   the role of nicotine addiction in sustaining smoking 
iii)  how to use NRT  (including safety concerns) 
iv)  coping with withdrawal symptoms.   
 
Support will be specific to the needs of pregnant women and may involve: 
i)   enlisting partner support 
ii)  a partner quit attempt 
iii) ensuring that the partner has information about smoking cessation services 
 
Study midwives will use brief cognitive - behavioural counselling, combining 
components from effective counselling strategies that are effective31, such as: 
i)  providing structure to quit attempts 
ii) agreeing a "contract" for any attempt 
 
A quit date which is within 2 weeks will be agreed and participants will be 
instructed to start using patches on this date.  
 
Local NHS stop smoking services will provide subsequent behavioural support 
sessions.  These follow up sessions will reinforce women’s reasons for quitting 
and strategies for success.  A standardised approach to follow up support 
sessions is important and NHS stop smoking service staff will be orientated 
towards this. If no local support is available or if the woman declines it, then the 
research midwife will provide further support as required.  
 
11. Statistical analysis plan 
 
General 
a) Primary outcome measure: The proportion of women who report prolonged 
and total abstinence from smoking immediately before child birth will be 
compared between treatment groups by Chi-squared test, on an intention to treat 
basis (all those randomised) with smokers lost to follow up considered to have 
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continued smoking. For this analysis, we will assume that women in each group 
use their allocated treatments as directed and no randomised participants will be 
excluded from analyses.  Baseline data on smoking behaviour and demographic 
information will be compared between groups, and adjustment made for any 
differences, using logistic regression.  
 
b) Child behaviour and development scores at 2 years: We will compare in 
children born to women in the control and intervention groups, using t-test (via 
log transformation) or the Mann-Whitney U statistic.  Again this will be done on 
an intention to treat basis. A small number of children will be born as multiple 
births (e.g. twins) and data for these cases will be clustered rather than 
independent.  Robust standard errors, or a similar appropriate statistical method 
will be used in analysis of child data to allow for this.  
 
There will be two analyses.  The first will be conducted upon data obtained 
around delivery.  The second will be conducted at 2 years after delivery, using 
data obtained between delivery and this time point.  Data collected for secondary 
outcomes will not be analysed until the trial has ended with respect to the 
primary outcome measure. 
 
c) Other outcomes 
 
i) Fetal birth outcomes (section 5b) and ii) Maternal birth outcomes (section 5c) 
will also be compared on an intention to treat basis between the 2 groups in the 
first analysis at delivery (as a & b above)  
 
As these outcomes relate to the safety of NRT in pregnancy we will also conduct 
an analysis of these outcomes comparing participants in each group who report 
using any patches with those in each group who report using none.  
 
d) Sub group analyses 
 
These will be conducted to investigate the relationship between i) baseline 
cotinine levels and cessation and ii) maternal educational level (proxy for socio-
economic status) and cessation.  We will model the relationship between smoking 
cessation, pre-treatment plasma cotinine levels and treatment group in a logistic 
regression, to establish whether there is effect modification by pre-treatment 
plasma cotinine and whether efficacy at given levels of plasma cotinine varies. 
The model will also establish whether or not smoking cessation is constant across 
all levels of pre-treatment plasma cotinine in the NRT group, or reduces with 
increasing pre-treatment plasma cotinine, which could be indicative of inadequate 
replacement of nicotine. We will use similar methods to investigate ii) above. 
 
Health economics 
Economic analysis will be undertaken to investigate short term and longer term 
potential cost-effectiveness of NRT in pregnancy.  The cost-effectiveness of NRT 
use by the general population has been established32 and a small number of 
studies have investigated the potential cost saving of smoking cessation 
interventions in pregnancy33, but few have used empirical data on costs of 
interventions.  Analyses for this study will be primarily undertaken from an NHS 
perspective.  Uptake of behavioural support and NRT will be monitored and costs 
of both estimated with both locally-specific and national average values.  The 
differential consequences in terms of length of maternal stay and post natal 
delivery to special care between the two arms of the trial will be used with the 
estimated costs of delivering interventions with and without NRT patches and 
differential smoking cessation rates to estimate the incremental cost-
effectiveness ratio.  Sensitivity analyses exploring assumptions made in 
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estimating the control state (no NRT) will be undertaken.  The primary health 
outcome will be maternal smoking cessation immediately before delivery and 
differences in health status at 6 months (from EQ5D data) will be converted into 
QALYs to allow cost-utility modelling.  Additionally, a range of modelling 
techniques will be used to estimate longer-term cost-utility from two year follow-
up data.  Epidemiological and economic models will be used to estimate lifetime 
gains in QALYs from smoking cessation and savings in health care 
expenditures32;34.   A full literature review will be undertaken to explore the 
potential for providing monetary estimates of the long term impacts on the child 
of their differential birth outcomes. 
 
Safety 
To minimise the likelihood of women or infants being harmed by unexpected 
effect(s) of nicotine that could not predicted from previous research, the Data 
Monitoring & Ethics Committee will have access to birth outcome data.  These 
data will be available for the DMEC to analyse as is considered appropriate to 
investigate whether or not significant or clinically-important differences arise 
between study groups (e.g. in birth weight).        
 
12. Safety reporting 
 
Nicotine has very low toxicity when used in NRT outside of pregnancy, but the 
impact of nicotine in pregnancy is not clearly defined.  Safety reporting, 
therefore, necessarily involves monitoring a range of adverse pregnancy 
outcomes, such that any previously-unknown adverse effect of NRT in pregnancy 
can be detected. 
 
a) The following will be considered adverse events (AEs): 
 
i) Withdrawal from patch treatment due to skin reaction or other symptom(s) 
which are potentially caused by NRT (listed in section 4.10 BNF)  
 
ii) Events requiring hospital admission which are related to the underlying 
pregnancy (see footnote)  
 
AEs will be reported in an annual safety report to the MHRA, REC and Sponsor. 
 
DMEC meetings will consider unblinded AE data and, if data indicates it 
appropriate, will recommend that individual AEs should be re-classified as SAEs, 
so that in-trial monitoring of such events is more rigorous. 
 
b) The following will be considered Serious Adverse Events (SAEs): 
 
Baby:  miscarriage, stillbirth, neonatal and post-neonatal death  
Maternal:  maternal death   
Other events requiring hospital admission apart from those 
related to the underlying pregnancy or a pregnancy related 
condition (see footnote for excluded hospital admissions)a   
                                                 
a
 The following pregnancy-related hospital admissions are not SAEs but will be treated as AEs: 
delivery (not AE or SAE), recognised pregnancy or postnatal complications, including pre-term 
delivery before 32 weeks, low birth weight (< 2,500g), birth injury, infection, thrombosis, 
haemorrhage, hypertensive disease, instrumental delivery (not AE or SAE), caesarean section (not AE 
or SAE), and antenatal admissions for pregnancy related diseases such as false labour, infection, 
thrombosis, haemorrhage, hypertensive disease, suspected or confirmed fetal compromise, vaginal 
bleeding  fetal congenital abnormalities, and infant hospital admissions.   Incidental hospital 
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Any other serious unexpected event. 
 
All SAEs will be reported on a standard form and assessed by Professor Jim 
Thornton or a named deputy to determine whether or not they should be 
considered as being Suspected Unexpected Serious Adverse Reactions 
(SUSARs) which are potentially-related to trial treatments. 
 
Life threatening or fatal SUSARs will be reported to the MHRA and REC within 7 
days (follow up report within 15 days) and also to relevant NHS trust R&D office 
according to local policies. 
 
Non life threatening SUSARs will be reported to the MHRA and REC within 15 days 
and also to R&D offices, as appropriate.   
 
SUSARs will also be reported to the DMEC chair along with the treatment 
allocation group of the trial subject and a cumulative count of SAE and SUSAR 
frequency in each trial arm. 
 
SAEs which are not considered SUSARs will be reported in an unblinded manner 
to each DMEC meeting and in the annual report to MHRA, REC and Sponsor with 
AEs. 
 
 
13. Publication policy 
 
The success of SNAP is dependant upon participating doctors, midwives and NHS 
stop smoking service staff who successfully recruit and treat patients within the 
trial.  For this reason, credit will be assigned to them in reports from the study 
and they will be named in the trial report.  The principal trial report will be 
authored by “The SNAP Trial Team”. 
 
14. Trial steering committee 
 
Mr Peter Brocklehurst (Chair) Director, National Perinatal Epidemiology Unit, 
University of Oxford 
 
Professor Peter Hajek 
 
Professor of Clinical Psychology, Tobacco 
Dependence Research Centre, Barts and The 
London, Queen Mary's School of Medicine and 
Dentistry 
 
Dr Carol Coupland Senior Lecturer in Medical Statistics, Division of 
Primary Care, University of Nottingham 
 
Mrs Sue Maguire Lay member 
 
Dr Michael Murphy Director, Childhood Cancer Research Group, 
University of Oxford 
 
 
                                                                                                                                            
admissions for minor, gastrointestinal diseases, respiratory, cardiac, renal skin, psychiatric and 
neurological problems. 
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15. Data monitoring and ethics committee 
 
Professor Janet Peacock (Chair) Professor of Health Statistics, Brunel University 
 
Professor Khalid Khan (till Oct 2008) Professor of Obstetrics, Gynaecology and Clinical 
Epidemiology, University of Birmingham 
 
Professor David Field Professor of Neonatal Medicine, University of 
Leicester 
Professor Christopher Butler (from Jan 
2009) 
Professor of Primary Care, Cardiff University 
 
16. Centres 
 
In each hospital recruiting centre there is a PI and a midwife lead (hospital 
based) and a NHS stop smoking service lead. 
 
 
 
Hospital recruiting centre 
 
 
NHS stop smoking service 
Derby City General Hospital Fresh Start  
 
Jonathon Allsop (PI), Julia Savage 
 
 
 
Mary Styles 
 
Kings Mill Centre, Mansfield New Leaf, Notts County tPCT 
 
Karen Glass (PI), Alison Witham 
 
 
Barbara Brady 
North Staffordshire University 
Hospitals 
North Staffordshire Quit Smoking 
Service 
 
Khaled Ismail (PI), Christine Kettle 
 
 
Deborah Richardson 
 
Nottingham City Hospital New Leaf, Nottingham 
 
Jim Thornton (PI), Amanda Lindley 
 
 
Indu Hari 
Queens University Medical Centre, 
Nottingham 
New Leaf, Nottingham 
 
Margaret Ramsey (PI), Amanda Lindley 
 
 
Indu Hari 
Leighton Hospital, Crewe Central Cheshire Stop Smoking 
Service 
 
Simon Cunningham (PI), Sandra Smith 
 
 
Paul Jackson 
Macclesfield District General 
Hospital 
Central Cheshire Stop Smoking 
Service 
 
Vince Hall (PI), Grace Hopps 
 
 
Paul Jackson 
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17. Funding 
The research costs of SNAP are funded by the NHS Health Technology 
Assessment Programme and the NHS Support Costs have been met from NHS 
R&D funds. 
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19. Data Collection Forms 
   
 
3 data collection forms will be designed for RMs to use as a paper record of data 
collected at i) baseline ii) one month after quit date and iii) delivery and 
immediately afterwards.  These will be finalised once the online database is 
completed (and if possible generated from this).  NB: These forms will record 
data obtained by RMs and will not be completed by trial participants.
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 Appendix A: Trial Process 
  1 Trial flow from recruitment to delivery      
  (primary outcome ascertainment) 
 
 
 
 
 
 
 
 
 
 
 
 
Research midwives in each centre are responsible for accurate data entry to internet hosted database, for sending blood samples to 
appropriate university departments and accurate paper copies of data collection sheets from i) baseline (pre-randomisation) ii) one 
month follow up and iii) delivery to the Nottingham Trial Co-ordinating Team. 
 
Prior to delivery, during hospital admission for delivery – data 
collected directly from trial participant to ascertain trial primary outcome.  
RM collects data as in section 9c, including biochemical verification of 
smoking cessation status.  If RM not available, delivery suite staff collect 
data.  If women missed prior to delivery, RM collects data within 4 weeks of 
birth, if necessary, visiting the homes of women who report smoking 
cessation to biochemically verify this. 
One month follow up: Women return to RM for further treatment between 
3 and 6 weeks after randomisation. Women who are not smoking, confirmed 
by exhaled CO given one month’s further patch supply (double blind).  Data 
outlined in section 9b collected.  Non-returners sent postal questionnaire 
by NTCT to obtain data.  RM conducts CO validation for women who report 
smoking cessation but do not wish to have further NRT (home visit if 
necessary). 
During initial visit, after consenting - women receive first session of 
behavioural support. Baseline pre-randomisation data and samples 
collected, as sections 9a i-iii. Women set a quit date within 2 weeks of this 
session and agree to stop smoking from this date.   
Women who do not 
consent leave at any point 
of process 
Further sessions of 
behavioural support 
 
delivered by staff from 
NHS stop smoking 
services 
or research midwife 
 
 delivered within 8 
weeks of randomisation 
Randomisation: (after initial visit and 1st behavioural support session).  
Mandatory, enrolment data (section 9a) entered into internet 
randomisation system.  RM is now allowed to randomise woman to 
intervention or control group.  4 weeks treatment (active or placebo 
transdermal patches) dispensed by pharmacy or RM with double blinding.  
Contact details of randomised women passed to NHS stop smoking service & 
trial participants given contact details for this service.   
Before attendance for U/S dating scan - all women due to attend sent 
trial patient information sheet or trial advert 
During attendance for U/S dating scan - RM identifies eligible women 
– as section 7  Women given PIS if not previously received. Initial trial 
visit organised 
Exclusions – as section 7 
Further data collection, after delivery.  RM collects data as in section 
9c from maternal or infant medical records.  
SNAP trial protocol Final version 7.0 11 June 2009 
 
 - 24 -  
2 Trial follow- up: delivery to infants’ 2nd birthdays 
 
 
All questionnaires & cards sent by Nottingham Trial Coordinating Team (NCTC) 
 
 
 
 
 
1 year : All infants sent 1st birthday card 
 
Non-respondents to questionnaire above: One 
postal reminder sent, followed by one 
telephone reminder. 
 
Not known at this address – use maternal 
grandparent contact details or ONS. 
6 months (infant age): Postal questionnaire 
measuring self reported smoking status and 
health economic data. One postal / one 
telephone reminder. 
2 weeks before 1st birthday: postal 
questionnaire to mother  
2 weeks before 2nd birthday: (infant age): 
Postal questionnaire to parents.  
Two years: (infant age): Postal questionnaire 
to GP / health visitor.  
Two years: All infants sent 2nd birthday card 
 
Non-respondents to questionnaire above: One 
postal reminder sent, followed by one 
telephone reminder. 
 
Not known at this address – use maternal 
grandparent contact details or ONS. 
Non-respondents at two years: One postal 
followed by one telephone reminder. 
 
 
 
Congratulations card 
sent, as appropriate, to 
mother after baby is born 
 
 
Christmas cards sent, 
as appropriate, to 
children born within trial 
Mailings to infants / parents 
Mailings to health professionals 
SNAP trial protocol Final version 7.0 11 June 2009 
 
 - 25 -  
Appendix B: Trial materials 
 
 
1 Patient information sheet 
  
2 Letter to patient, accompanying patient information sheet 
 
3 Sample questionnaire for use in subject identification 
 
4 Patient consent form 
 
5 Letter to GPs / consultants about enrolled patients 
 
6 Postal questionnaire for women who do not return for treatment at one 
 month post quit date 
 
7 Letter to accompany postal questionnaire sent at one month after quit 
 date 
 
8 Postal questionnaire sent out at six months after childbirth 
 
9 Letter to accompany questionnaire sent out six months after child birth 
 
10 Maternal questionnaire sent out at 1 year after childbirth 
 
11 Letter to accompany parental questionnaire sent out at 1 year after child 
 birth 
 
12 Questionnaire to participant sent out at 2 years after childbirth 
 
13 Letter to accompany parental questionnaire sent out at 2 years after child 
 birth, plus advance notification card, and reminder letter 
 
14 Health professional questionnaire sent at 2 years after childbirth 
 
15 GP Letter to accompany health professional questionnaire sent at 2 years 
 after childbirth 
 
16 Trial advert and information leaflet 
 
17 Colouring competition sheet sent at 2 years after childbirth 
 
 
 
 
  
 
